G12D can cause lung cancer rapidly, but is not sufficient to induce thyroid cancer. It is not clear whether long-term serum thyroid stimulating hormone (TSH) stimulation can promote KRAS G12D -mediated thyroid follicular cell transformation. In the present study, we investigated the effect of long-term TSH stimulation in KRAS G12D knock-in mice and the role of Sprouty1 (SPRY1) in KRAS G12D -mediated signaling. We used TPO-KRAS G12D mice for thyroid-specific expression of KRAS G12D under the endogenous KRAS promoter. Twenty TPO-KRAS G12D mice were given anti-thyroid drug propylthiouracil (PTU, 0.1% w/v) in drinking water to induce serum TSH and 20 mice were without PTU treatment. Equal number of wild-type littermates (TPO-KRAS WT ) was given the same treatment. The expression of SPRY1, a negative regulator of receptor tyrosine kinase (RTK) signaling, was analyzed in both KRAS G12D -and BRAF V600E -induced thyroid cancers. Without PTU treatment, only mild thyroid enlargement and hyperplasia were observed in TPO-KRAS G12D mice. With PTU treatment, significant thyroid enlargement and hyperplasia occurred in both TPO-KRAS G12D and TPO-KRAS WT littermates. Thyroids from TPO-KRAS G12D mice were six times larger than TPO-KRAS WT littermates. Distinct thyroid histology was found between TPO-KRAS G12D and TPO-KRAS WT mice: thyroid from TPO-KRAS G12D mice showed hyperplasia with wellmaintained follicular architecture whereas in TPO-KRAS WT mice this structure was replaced by papillary hyperplasia. Among 10 TPO-KRAS G12D mice monitored for 14 months, two developed follicular thyroid cancer (FTC), one with pulmonary metastasis. Differential SPRY1 expression was demonstrated: increased in FTC and reduced in papillary thyroid cancer (PTC). The increased SPRY1 expression in FTC promoted TSH-RAS signaling through PI3K/AKT pathway whereas downregulation of SPRY1 by BRAF V600E in PTC resulted in both MAPK and PI3K/AKT activation. We conclude that chronic TSH stimulation can enhance KRAS G12D -mediated oncogenesis, leading to FTC. SPRY1 may function as a molecular switch to control MAPK signaling and its downregulation by BRAF V600E favors PTC development. Thyroid cancer is the most common type of endocrine malignancies and its incidence is rising rapidly in recently years, especially among women. 1 Histologically, it can be classified into papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), and anaplastic thyroid cancer (ATC). PTC is the most common type of differentiated thyroid carcinomas, accounting for more than 80% of thyroid cancer, and FTC accounts for 15%. 2 The BRAF V600E is the most common genetic alterations in PTC with overall rate of 44%, [3] [4] [5] and RAS (HRAS, KRAS, or NRAS) mutations are found in about 50% of FTC and can also been found in benign adenomas. 6, 7 In the earlier studies, several transgenic mouse models were created to study the molecular mechanisms of RAS-mediated transformation of thyroid follicular cells in vivo. [8] [9] [10] Both PTC and FTC were developed from overexpression of a mutant RAS gene under TG promoter, which may not reflect the activity of endogenous mutant RAS gene expressed at the
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G12D
-mediated thyroid follicular cell transformation. In the present study, we investigated the potential of long-term TSH stimulation on thyroid cancer development in KRAS G12D knock-in mice targeted to express its oncoprotein in thyroid at the physiological level. We also studied the role of SPRY1 in the regulation of KRAS
-vs BRAF V600E -mediated signaling.
MATERIALS AND METHODS Experimental Animals

LSL-KRAS
G12D (obtained from The Jackson Laboratory, ME, USA), LSL-BRAF
V600E
, and TPO-Cre strains have been described previously. [17] [18] [19] 
Genotyping of TPO-KRAS
G12D or TPO-BRAF V600E Strain Genotyping of TPO-Cre mediated recombination of LSL-KRAS G12D or LSL-BRAF V600E targeted allele has been described previously. 17, 19 Briefly, the following primers were used to detect LSL-KRAS G12D recombination in mouse tissue: primer 1, 5′-GTCTTTCCCCAGCACAGTGC-3′, primer 2, CTCTTGCCTACGCCACCAGCTC-3′, and primer 3, 5′-AG CTAGCCACCATGGCTTGAGTAAGTCTGCA-3′. Primer 1+2 detects wild-type allele yielding a product of 622 bp. Primer 1+2 also detects Cre-recombined KRAS G12D allele (Lox-KRAS G12D ) yielding a product of 650 bp. This product is larger than the wild-type allele due to the presence of LoxP site that remains after Cre-mediated recombination. Primer 2 +3 detects the LSL-KRAS G12D allele yielding a product of 500 bp. Multiplex PCR containing three primers was used: 95°C for 10 min followed by 35 cycles of amplification (95°C for 1 min, 60°C for 1 min, 72°C for 1 min with final extension at 72°C for 10 min). The following primers were used to detect LSL-BRAF V600E recombination: primer A, 5′-AGTCAATCATCCACAGAGACCT-3′, primer B: 5′-GCTTG GCTGGACGTAAACTC-3′, and primer C, 5′-GCCCAGG CTCTTTATGAGAA-3′. Primer A+C detects the wild-type allele yielding a product of 466 bp. Primer A+C also detects Cre-recombined allele (Lox-BRAF V600E ) yielding a product of 518 bp. Primer B+C detects the LSL-BRAF V600E allele yielding a product of 140 bp. The PCR conditions are at 95°C for 5 min followed by 35 cycles of amplification (95°C for 1 min, 60°C for 1 min, 72°C for 1 min with a final extension at 72°C for 10 min).
Anti-Thyroid Drug Treatment
TPO-KRAS
G12D mice (4-10 weeks of age) were divided into two groups and given 0.1% (w/v) anti-thyroid drug propylthiouracil (PTU, Sigma-Aldrich, MO) in drinking water ad libitum, changed once weekly, to induce serum TSH. One group (n = 10) was observed for 8 months and the other group (n = 10) was observed for 14 months. Twenty TPO-KRAS G12D mice were also divided into two groups (10 in each group) without PTU treatment, and observed for 8 and 14 months, respectively. Forty wild-type mice (TPO-KRAS WT , 10 in each group) were given the same treatment as TPO-KRAS G12D mice.
Thyroid Hormone Measurements
Blood was collected by cardiac puncture. Serum TSH was measured using MILLIPLEX MAP Mouse Pituitary Magnetic Bead Panel following the manufacturer's instruction (EMD Millipore Corporation, Billerica, MA, USA). Serum total T4 was measured using MILLIPLEX MAP Steroid/Thyroid Hormone Magnetic Bead Panel (EMD Millipore Corporation).
Tumor Cell Culture A PTC tumor from a 4-month-old TPO-BRAF V600E mouse was collected aseptically using blunt dissection and mechanically dissociated by mincing and passaged through a 40-μM mesh sterile screen, and suspended in DMEM/F12 growth medium (10% fetal bovine serum, 100 units/ml penicillin, 100 μg/ml streptomycin). Cells were further dissociated by incubation in the growth medium containing 100 U/ml type I collagenase (Sigma-Aldrich) and 1.0 U/ml dispase I (Roche Diagnostics, Indianapolis, IN, USA) at 37°C rocking water bath for 60 min. The cell suspension was washed twice and resuspended in 10 mm culture dish with DMEM/F12 growth medium containing 2 mU/ml bovine TSH (Sigma-Aldrich) to establish a BVE cell line (BRAF V600E -induced tumor cell line). The genetic background was confirmed by genotyping.
Quantitative Real-Time Reverse Transcriptase-PCR Analysis for SPRY1 Expression Total RNA was isolated from thyroid of TPO-KRAS WT mice treated with PTU, PTC of TPO-BRAF V600E , or FTC of TPO-KRAS G12D mice by the quanidinium thiocyanate-phenolchloroform method as described previously. 20 The integrity of TSH mediated RAS transformation of thyroid follicular cells M Zou et al RNA was verified by denaturing gel electrophoresis. In all, 2 μg of each total RNA was reverse-transcribed to cDNA using the Promega RT system (Promega, Madison, WI, USA). LightCycler DNA Master SYBR Green 1 kit was used for quantitative real-time PCR analysis. 21 The cDNA mix was diluted 10-fold, and 2 μl of the dilution was used for real-time PCR. PCR primers for the 114-bp SPRY1 cDNA fragment are 5′-GCGGAGGCCGAGGATTT-3′ (forward) and 5′-ATCAC CACTAGCGAAGTGTGGC-3′ (reverse). The forward primer spans the junction of exon 1 and exon 2 over 1.7 kb intron 1 so that contaminated genomic DNA will not be amplified. The SPRY1 cDNA fragment was verified by DNA sequencing. The mRNA level of housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control, and a 155-bp PCR product was amplified using the following two primers: 5′-ATGTTCCAGTATGACTCCACT CACG-3′ (forward) and 5′-GAAGACACCAGTAGACT CCACGACA-3′ (reverse). The PCR conditions are 95°C for 30 s followed by 30 cycles of amplification (95°C for 10 s, 50°C
for 5 s, and 72°C for 10 s). The resulting concentration of SPRY1 PCR products was normalized by comparison with GAPDH and was used to determine the relative mRNA level of SPRY1 in thyroid tumors.
Histology and Immunohistochemistry
Histology and immunohistochemical staining was described previously. 22 Briefly, 4-μm-thick formalin-fixed paraffinembedded tissue sections were prepared and stained with hematoxylin and eosin or SPRY1 (1:50 dilution, Abcam, Cambridge, MA, USA), p-ERK, or p-AKT antibody (1:50 dilution, Cell Signaling Technology, Danvers, MA, USA). Histological diagnosis was performed by a thyroid pathologist (MA) blinded to the genotype and the treatment status of the animal. DAKO LSAB+kit, HRP was used for immunostaining (DAKO, Carpinteria, CA, USA). The sections were counterstained with Mayer's haematoxylin.
Regulation of TSH Signaling by SPRY1
Mouse SPRY1 cDNA in pCMV6 expression vector was obtained from OriGene (Rockville, MD, USA). BVE cell line was transfected with either pCMV6 vector or mSPRY1/ pCMV6 using Lipofectamine (Invitrogen, CA). The culture medium was changed to DMEM/F12 growth medium 16 h after transfection, and the transfected cells were cultured for additional 48 h in the presence or absence of 10 mU/ml bTSH. The expression of SPRY1, phospho-ERK, and phospho-AKT was determined by western blot analysis.
Western Blot Analysis BVE cell line was transfected with mouse SPRY1 cDNA under the control of CMV promoter (Origen). 40 μg of protein was loaded onto a 12% SDS-polyacrylamide gel. Proteins were transferred onto a PVDF membrane and subject to western blot analysis using anti-phospho-ERK 1/2, and phosphor-AKT antibody (1:1000, Cell Signaling Technology) or anti-SPRY1 (1:1000, Abcam).
Bioinfomatic Anylysis of Human PTC Samples
The expression profiles of SPRY1, SPRY2, SPRY3, and SPRY4 in the TCGA data set of 572 PTC samples 23 were analyzed using UCSC cancer genomics browser (https://genomecancer.soe.ucsc.edu/proj/site/hgHeatmap/).
Statistical Analysis
Unpaired Student's t-test (two-tailed) was used. A P-value of 0.05 or less was considered as significant.
RESULTS
Without PTU treatment, only mild thyroid enlargement and hyperplasia were observed in TPO-KRAS G12D mice (Figure 1b) . The thyroids were about two times larger as compared with those from the TPO-KRAS WT mice. Thyroid cancer development was not observed among 10 mice monitored for up to 14 months. With PTU treatment, significant thyroid enlargement with multinodular goiters and hyperplasia occurred in both TPO-KRAS G12D and TPO-KRAS WT mice (Figure 2a ). Massive thyroid enlargement was found in TPO-KRAS G12D mice: thyroids of TPO-KRAS G12D mice were about six times larger than TPO-KRAS WT mice (118.75 ± 13.15 mg vs 21.11 ± 6.33 mg, Po0.001, Figure 2b ), indicating that TSH can cooperate with KRAS G12D to promote thyroid growth and hyperplasia. Interestingly, thyroid histology of TPO-KRAS G12D mice showed nodular hyperplasia with wellmaintained follicular architecture whereas in TPO-KRAS WT mice such follicular architecture was replaced by papillary hyperplasia (Figure 2c ). However, PTC was not diagnosed due to lack of characteristic nuclear features such as nuclear grooves, intranuclear cytoplasmic inclusion, fine chromatin texture, and nuclear envelope irregularity. As shown in Figure 2d , serum TSH was significantly elevated in PTUtreated mice as compared with the control (24 370.8 ± 12 942.5 vs 426.4 ± 9.65 pg/ml, Po0.01). Serum T4 was significantly reduced in PTU-treated mice as compared with the control (5.21 ± 1.31 vs 22.68 ± 6.23 ng/ml, Po0.05). Among 10 TPO-KRAS G12D mice monitored for 14 months, two developed follicular thyroid cancer (FTC, Figure 3a) and one with pulmonary metastasis (Figure 3b ). Since the cellular features were indistinguishable between follicular hyperplasia and cancer, the diagnosis of FTC was based on the invasion of surrounding tissues such as blood vessel and neck muscle (Figure 3a) , and pulmonary metastasis (Figure 3b ). Among 10 TPO-KRAS WT mice monitored for 14 months under PTU treatment, no tumor development was observed.
The Sprouty (SPRY) family of proteins is involved in the negative feedback regulation of growth factor-mediated MAPK activation. 24 To understand why TSH stimulation caused only FTC, but not PTC, we investigated SPRY1 expression in thyroid tumors from TPO-KRAS G12D and TPO-BRAF V600E mice. SPRY1 mRNA level was significantly higher in KRAS
G12D
-induced FTC (9.23 ± 0.56) as compared with KRAS WT control (1.03 ± 0.15, Po0.01, Figure 4a ). SPRY1 expression was also increased in KRAS G12D thyroid without PTU treatment (2.1 ± 0.2, Po0.01, Figure 4a) , but the expression level was much lower than under PTU treatment, suggesting that the increased SPRY1 expression may be a compensatory mechanism to counter TSH-mediated growth stimulation. In contrast, SPRY1 mRNA level was significantly lower in BRAF V600E -induced PTC (0.31 ± 0.17) as compared with BRAF WT control (1.00 ± 0.12, Po0.05, Figure 4b ). The serum TSH was greater than 50 000 pg/ml (beyond the detection limit of the kit) and T4 was 3.87 ± 0.68 in TPO-BRAF V600E mice (n = 6) as compared with 445.2 ± 72.21 in TSH and 29.03 ± 3.62 in T4 from TPO-BRAF WT mice (n = 6), consistent with previous report that TPO-BRAF V600E mice have severe hypothyroidism. 13 The increased SPRY1 expression in FTC was confirmed by immunohistochemistry analysis. As shown in Figure 4c , increased SPRY1 and p-AKT expression was observed in FTC (b and e) with normal p-ERK expression (h). In PTC, both p-ERK and p-AKT expression were increased (f and i). Although downregulation of SPRY1 expression in PTC was not clearly shown by immunohistochemistry (Figure 4cC) , it was confirmed by western blot analysis, showing inverse correlation between SPRY1 expression and p-ERK activation (Figure 4d) .
To further investigate the role of SPRY1 in the regulation of TSH-mediated signaling, we used BVE cell line (derived from BRAF V600E -induced PTC tumor) as a model, for it has low SPRY1 expression. The cell line was transfected with mouse SPRY1 cDNA and treated with or without TSH. As shown in Figure 5 , SPRY1 expression reduced p-ERK expression, and TSH stimulation only activated p-ATK when SPRY1 expression was increased. When SPRY1 expression was reduced, TSH stimulation increased both p-ERK and p-ATK expression ( Figure 5 ). These data suggest that SPRY1 may act as a molecular switch to control thyroid follicular cells to go through either MAP kinase (RAF-MEK-ERK) or PI3 kinase (PI3K/AKT) signaling pathway. When SPRY1 is upregulated by KRAS
, MAPK pathway is inhibited and only PI3K/AKT pathway is utilized, resulting in FTC. When SPRY1 is downregulated by BRAF
V600E
, thyroid follicular cells may go through both MAPK and PI3K/AKT pathways to initiate PTC.
Finally, we performed bioinformatic mining of the recent TCGA data set of 572 human PTC samples to compare SPRY gene (SPRY1, SPRY2, SPRY3, and SPRY4) expression between classic PTC (CPTC) and follicular variant PTC (FVPTC). FVPTC shares many molecular and pathological features with FTC. RAS mutation is frequently detected in FVPTC as compared with frequent BRAF mutation in CPTC. As shown in Figure 6 , the SPRY1 and SPRY4 expression is reduced in normal thyroids. The expression of SPRY2 and SPRY3 tends to increase in normal thyroids and is variable in both CPTC and FVPTC. The SPRY1 expression is also variable in CPTC and FVPTC. In CPTC, increased SPRY1 expression is present in 36 
DISCUSSION
In the present study, we have demonstrated that KRAS G12D mutation alone is not sufficient to induce oncogenic transformation of thyroid follicular cells. With long-term TSH stimulation, KRAS G12D can promote thyroid growth and hyperplasia, and eventually result in oncogenic transformation into follicular thyroid cancer. This demonstrates the significant oncogenic role of TSH in thyroid tumorigenesis: without TSH stimulation, thyroid cancer would not be able to develop or progress even in the presence of KRAS G12D or BRAF V600E . 25 The animal model in the current study is very similar to congenital hypothyroidism in humans, which is caused by defects in thyroid hormone synthesis. 26 High levels of TSH are often present in patients with congenital hypothyroidism due to poor management or patients' non-compliance to treatment. We and others have reported thyroid cancer development as a result of long-term TSH stimulation. 27, 28 Although both PTC and FTC were reported in those cases, BRAF mutation was found only in patients with PTC. 29 RAS mutations have been reported in both benign thyroid goiters and cancers, 30 indicating that additional factors are required to initiate malignant transformation. The current study has demonstrated that chronic TSH stimulation is one of the factors required for RAS-mediated carcinogenesis.
TSH stimulates growth and differentiation of thyroid follicular cells through its G protein-coupled receptor. TSH can activate both cAMP-protein kinase A (PKA) pathway for differentiation 31 and RAS-PI3K pathway for proliferation. 32, 33 RAS allows growth promoting signals through both MAPK (RAF-MEK-ERK) and PIK3CA/AKT pathways. Previous studies have shown that cAMP can inhibit RAS-mediated signals to MAPK by blocking RAF-1 activation via RAP1. 34, 35 Under these circumstances, PI3K signaling is the main mediator of RAS effects. RAP1 is a member of the RAS family of small G proteins that transmit signals from cAMP- TSH mediated RAS transformation of thyroid follicular cells M Zou et al PKA pathway to MAPK pathway by interaction with BRAF. 36 Without BRAF, GTP-loaded RAP1 blocks RAS activation of RAF-1, thereby inhibiting MAPK signaling. 37 In a mouse model with constitutive RAP1 activation in thyroid, FTC was not developed until given 12 months goitrogen treatment, indicating that TSH signaling is required and is probably via RAS-PI3K pathway for FTC initiation. 38 In two different FTC mouse models, TSH signaling is constantly activated with simultaneous activation of either PI3K/AKT 39, 40 or phospholipase C pathway. 41 FTC was developed in all mice with PI3K/ AKT activation, suggesting that PI3K is an important mediator of RAS effects in TSH-induced FTC. FTC can develop rapidly without TSH signaling when both RAS and PI3K/AKT pathways are constitutively activated. 42 Although MAPK is activated in these mice, 42 PI3K signaling probably predominates over MAPK, resulting in FTC phenotype. Since serum TSH is very low in these mice, MAPK activation may reflect the loss of cAMP-mediated inhibition of RAS signals to MAPK. 43 TSH signaling promotes the tumorigenesis of PTC, 13 indicating a cross-talk between TSH-cAMP-PKA pathway and MAPK pathway. 37 As discussed above, RAP1 may be one of the molecular switches to control TSH-cAMP signaling through either RAS-PI3K to initiate FTC or RAS-MAPK to induce PTC. In the current study, we have identified that SPRY1 is another molecular switch to regulate RAS-MAPK signaling. SPRY1 has been reported as a candidate tumorsuppressor gene in medullary thyroid carcinoma 44 and its expression is decreased in human prostate cancer. 45 We also found reduced SPRY1 expression in human PTC with BRAF V600E (data will be presented elsewhere). Concomitant loss of SPRY1 and SPRY2 results in hyperactive MAPK signaling and low-grade prostatic intraepithelial neoplasia. 46 However, when SPRY1 and SPRY2 loss-of-function occurs in the context of loss of one Pten allele, aberrant activation of AKT and invasive neoplasia occur, suggesting that Sprouty genes can negatively regulate the PI3K/AKT pathway as well. 46 Indeed, PI3K/AKT activation has been reported in PTC patients with BRAF
V600E
. 47 Our data also demonstrate the activation of both MAPK and PI3K/AKT pathways in BRAF V600E -induced PTC when SPRY1 expression is reduced. In KRAS
G12D
-induced lung cancer, SPRY2 is upregulated via negative feedback loop to inhibit MAPK signaling. 48 However, we only found SPRY1 upregulation in KRAS
-induced FTC and SPRY2 expression was not changed (data not shown). The differential SPRY1 expression in TPO-KRAS G12D and TPO-BRAF V600E mice indicates that SPRY1 can selectively regulate TSH-mediated RAS signaling pathways in thyroid: favoring MAPK pathway and PTC initiation when its expression is downregulated and PI3K/AKT pathway and FTC initiation when its expression is upregulated. It has been reported that supraphysiologic expression of a mutant RAS can result in PTC or mixed papillary-follicular features in early transgenic mice studies, 8 ,10 which appears to be contradictory to our hypothesis. However, overexpressed mutant RAS beyond physiological level may escape SPRY1-mediated feedback inhibition of MAPK signaling and induce PTC.
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